Provide feedbackProvide feedback

Home :: Endocrinology

Short, long sleep duration associated with increased likelihood of type 2 diabetes in middle-aged women

Wednesday, April 23 2008 | Comments

Among middle-aged women, those with a self-reported sleep duration of =8 hours are more likely to have type 2 diabetes relative to those with a sleep duration of 7 hours, according to results of the Finnish type 2 diabetes (FIN-D2D) survey. However, the survey findings did not reveal a similar association in middle-aged men.

The FIN-D2D survey was conducted in 2004 and 2005 to evaluate the FIN-D2D Project, a community-based diabetes prevention program. Researchers selected 4,500...

Among middle-aged women, those with a self-reported sleep duration of <=6 hours or >=8 hours are more likely to have type 2 diabetes relative to those with a sleep duration of 7 hours, according to results of the Finnish type 2 diabetes (FIN-D2D) survey. However, the survey findings did not reveal a similar association in middle-aged men.

The FIN-D2D survey was conducted in 2004 and 2005 to evaluate the FIN-D2D Project, a community-based diabetes prevention program. Researchers selected 4,500 individuals aged 45 to 74 years from the National Population Register to participate; 1,336 men and 1,434 women were included in the current analysis.

All of the participants completed a health examination, an oral glucose tolerance test (OGTT), and a sleep questionnaire.

The mean self-reported sleep duration was 7.3 hours for both women and men. Among the women, the researchers observed a significant U-shaped relationship between sleep duration and diabetes prevalence, which remained significant in adjusted analyses. Although the researchers observed a tendency toward the same U-shaped association in men, this association was not significant in adjusted analyses.

The adjusted odds ratio for having a diabetes diagnosis prior to the survey was 2.55 (95% CI, 1.21-5.35) among women who slept <=6 hours per night and 1.76 (95% CI, 1.12-2.61) among those who slept >=8 hours per night, relative to those who slept 7 hours per night. Similarly, the adjusted odd ratios for having either previously diagnosed diabetes or diabetes detected at the time of the survey health exam were 1.56 (95% CI, 0.95-2.58) and 1.71 (95% CI, 1.13-2.61), respectively.

The authors acknowledged that their study was limited by the overall participation rate (62%), the cross-sectional design, the lack of multiple glucose measurements and objective sleep measures, and the fact that they did not consider menopause status or hormone replacement therapy use in their analyses.  (Tuomilehto H, et al. Sleep Med 2008;9:221-227.)

In an accompanying editorial, Peter Nilsson of Lund University in Sweden noted that these findings, which show a stronger association between sleep duration and diabetes in women than in men, contradict most of the other published literature on the subject.

Nilsson added that intervention studies would need to be undertaken to truly evaluate the relationship between sleep quality/duration and glucose tolerance/type 2 diabetes, although such studies are unlikely to be conducted.

As a result, he advised, "[B]oth men and women should be studied in order to find ways to normalize their sleep habits to avoid consequences of disease and even increased mortality risk, taking into account the interindividual range of what is called normal sleep length." (Sleep Med 2008;9:219-220.)

Latest News

Lilly, Pelikan Technologies join to promote diabetes education Verusmed

Wednesday, April 23 2008 | Comments
Eli Lilly and Co. and Pelikan Technologies Inc. signed a 3-year agreement to promote awareness and education in the management and treatment of diabetes. The companies will focus on education about insulin therapy, insulin delivery devices, lifestyle management, new technologies, and glucose monitoring.

Pelikan manufactures diagnostic and monitoring devices, such as the Pelikan Sun electronic...

Sanofi-Aventis, Genfit drop collaborative development of 2 diabetes drugs Verusmed

Wednesday, April 23 2008 | Comments
Sanofi-Aventis Group discontinued its collaboration with Genfit to develop AVE8134 and AVE0847, 2 peroxisome proliferator-activated receptor agonists in Phase IIa clinical trials for the treatment of type 2 diabetes and dyslipidemia.

The French biopharmaceutical company said though the collaboration on the 2 compounds has halted, their partnership with Sanofi on a third type 2...


Surrogate markers of insulin resistance modestly predict diabetes, CVD, study shows Verusmed

Wednesday, April 23 2008 | Comments
Evidence Grade 2 What's This?
Surrogate markers of insulin resistance, such as the homeostasis model assessment of insulin resistance (HOMA-IR), have been used to evaluate insulin resistance as a predictor of diabetes and cardiovascular disease. New research suggests these markers have modest performance as predictors when the commonly used cutoff for insulin resistance is applied (ie, the top 25% of HOMA-IR values).

Baseline insulin resistance was calculated for 2,720 participants from the Framingham...

GLP-1, inflammation markers might contribute to increased risk of type 2 diabetes in black patients Verusmed

Wednesday, April 23 2008 | Comments
Severely obese, black adolescents have higher concentrations of inflammatory markers and lower glucagon-like peptide-1 (GLP-1) concentrations during an oral glucose tolerance test (OGTT) than do obese white patients, investigators found. These findings, they added, might help explain the higher risk of type 2 diabetes among black adolescents. 

An OGTT was administered to 49 subjects aged 11 to 18 years (black participants, n=37; white participants, n=12) who had a body mass...